Fermenta Biotech Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Fermenta Biotech Ltd trades at ₹432, building a base and 6 weeks into that stage. That is +30.7% against its own 200-day average. It sits at 100% of a 52-week range of ₹263 to ₹432. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 7 straight weeks.

Today the stock is building a base — week 6 of stage 1. At ₹432 it trades +30.7% versus its 200-day average and sits at 100% of its 52-week range (₹263–₹432).

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +614% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 7 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 63rd percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Fermenta Biotech Ltd trades at 20.2× P/E, mid-range by its own standards (63rd percentile). Its long-run median P/E is 15.2×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 20.2× is mid-range by its own standards (63rd percentile), against a long-run median of 15.2× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved −6.6% against a +16.0% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +6.8%/yr price move, ~+6.7%/yr came from earnings growth and ~+0.1 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Fermenta Biotech Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 10 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

55.8/100 — rank 6 of 14 in Pharma - API · 70% evidence confidence

Fermenta Biotech Ltd scores 55.8 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 6. Price leads the evidence: RS versus the benchmark is 30.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation.

The four contributions add to the total exactly: 11.4 + 18 + 11.3 + 15.1 = 55.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Fermenta Biotech Ltd reported ₹122 Cr of revenue in the Mar 26 quarter, −12.9% year on year. Over 10 years it has compounded at 12.9% a year. The last full year, FY26, came in at ₹523 Cr. The last four reported quarters add to ₹525 Cr.

Fermenta Biotech Ltd reported ₹122 Cr of revenue in the Mar 26 quarter, −12.9% year on year. Over 10 years it has compounded at 12.9% a year. The last full year, FY26, came in at ₹523 Cr. The last four reported quarters add to ₹525 Cr.

FY26 revenue came in at ₹523 Cr (+11.8% on the year), capping 10 years at 12.9% compound. The latest quarter (Mar 26) printed ₹122 Cr, −12.9% year on year.

Pace check: the last four quarters averaged +21.5% growth against the decade's 12.9% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +11.9% over the last 4 quarters against +25.2%/yr over the last 8 — rolling over.

→ Revenue slipped — did margins hold as it scaled? Next: 16.0% this quarter (−10.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Fermenta Biotech Ltd's operating margin is 16.0% in the Mar 26 quarter, −10.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 5.0% to 39.0%. The current quarter sits inside that band.

Fermenta Biotech Ltd's operating margin is 16.0% in the Mar 26 quarter, −10.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 5.0% to 39.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 16.0%, −10.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 5.0%–39.0%.

🚨 Why the margin moved: operating margin went −10.0 pp year on year while gross margin went +3.5 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins slipped — did that reach the bottom line? Next: profit −42.4% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Fermenta Biotech Ltd earned ₹19.0 Cr of net profit in the Mar 26 quarter, −42.4% year on year. Full-year FY26 profit was ₹70.0 Cr. The 10-year compound rate is 42.7%. That is 15.6% of the quarter's revenue. The same quarter a year earlier earned ₹33.0 Cr. 3 of the last 12 reported quarters were loss-making.

Fermenta Biotech Ltd earned ₹19.0 Cr of net profit in the Mar 26 quarter, −42.4% year on year. Full-year FY26 profit was ₹70.0 Cr. The 10-year compound rate is 42.7%. That is 15.6% of the quarter's revenue. The same quarter a year earlier earned ₹33.0 Cr. 3 of the last 12 reported quarters were loss-making.

Mar 26 profit was ₹19.0 Cr, −42.4% year on year. On the full year, FY26 printed ₹70.0 Cr (−7.9%), and the 10-year compound rate is 42.7%.

🚨 Why profit moved: revenue contributed −12.9% and the margin −10.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit −15.7% vs revenue +21.5%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

→ Profit rose — but did the cash follow? Next: 110% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 110% of Fermenta Biotech Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹93.0 Cr of operating cash against ₹70.0 Cr of profit. After ₹12.0 Cr of capital spending, ₹81.0 Cr was left as free cash.

FY26: operating cash of ₹93.0 Cr against reported profit of ₹70.0 Cr, leaving free cash of ₹81.0 Cr after ₹12.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 110% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 110%: the cash cycle tightened 117 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

→ So follow the cash to where it goes. Next: a 221-day cycle and ₹−8.0 Cr of building.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Fermenta Biotech Ltd's cash conversion cycle runs 221 days in FY26, down from 338 days in FY21. Capital spending ran ₹−8.0 Cr over the last 3 years. At FY26 sales of ₹523 Cr each day of that cycle holds about ₹1.4 Cr, so roughly ₹317 Cr sits inside the business at any moment.

FY26: debtors at 78 days, inventory at 290 days — roughly 9.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 221 days, tighter than FY21's 338.

The full loop: cash goes out to suppliers and production on day 0; stock waits 290 days to sell; customers pay about 78 days after that; and suppliers themselves are paid at 147 days — netting out to the 221-day cycle.

In money terms: at FY26 sales of ₹523 Cr, each day of the cycle holds about ₹1.4 Cr — so the 221-day loop keeps roughly ₹317 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹−8.0 Cr over the last 3 fiscal years against ₹71.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹13.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 21% and the ROIC − WACC spread is +0.5 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Fermenta Biotech Ltd earns a ROCE of 21% in FY26. That is up from a trough of 0% in FY23. Return on invested capital clears the cost of that capital by +0.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 13.4% net margin on 0.81× asset turns.

FY26 ROCE is 21%, recovered from a FY23 trough of 0% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 13.4% net margin × 0.81× asset turns × 1.60× balance-sheet leverage ≈ 17.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 12.5% − 12.0% = a +0.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.28.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Fermenta Biotech Ltd carries total debt of ₹113 Cr against shareholder equity of ₹401 Cr as of Mar 26, a debt-to-equity of 0.28 — effectively unlevered. On the annual view that ratio went from 0.64 in FY22 to 0.28 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹113 Cr against shareholder equity of ₹401 Cr — a debt-to-equity of 0.28. On the annual view, debt-to-equity went from 0.64 (FY22) to 0.28 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: Promoters added 2.0 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters added 2.0 points of Fermenta Biotech Ltd over 8 quarters, the biggest move on the register. That takes promoters to 64.1% of the company. Foreign institutions moved +0.1 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +2.0 points over 8 quarters to 64.1%; Foreign institutions: +0.1 points over 8 quarters to 0.1%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.

Why the register moved: promoters drove it (+2.0 points) — steady accumulation by institutions reading the same numbers this page reads.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Fermenta Biotech Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions